drugset / Trial / NCT01284322

Fresolimumab In Systemic Sclerosis

NCT01284322 ↗

Phase 1 Completed 18 enrolled Boston University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.

Timeline

Start
2011-01
Primary completion
2013-06
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fresolimumab Protein / enzyme biologic 1 mg/kg Intravenous
Subject Fresolimumab Protein / enzyme biologic 5 mg/kg Intravenous

Indications